@article{ff9d1ebd-04bb-4098-8310-e49ba9153163,
  abstract     = {{<p>INTRODUCTION: We evaluated associations between phosphorylated au 217 (p-tau217), p-tau181, p-tau231, and vascular risk factors with cognitive outcomes across the Alzheimer's disease (AD) continuum. METHODS: Baseline plasma p-tau concentrations and vascular risk factors were assessed in 277 Consortium for the Early Identification of Alzheimer's Disease–Quebec (CIMA-Q) participants. Associations between these markers, cognition, and clinical progression over on average 3.10 years were examined. RESULTS: Higher plasma p-tau levels were associated with worse cognition at baseline and over time, with the strongest effect observed with p-tau217 in cognitively impaired individuals (β = -0.49, p &lt; 0.001). Hypertension was further linked to steeper memory and executive function decline (β = −0.10, both p = 0.04) in this group, and it amplified the effect of p-tau217 on cognitive decline across the whole group. Higher p-tau217 levels were associated with cognitive decline in cognitively unimpaired individuals, and it also predicted progression from mild cognitive impairment (MCI) to AD dementia (hazard ratio [HR] = 1.22, p = 0.016). DISCUSSION: Plasma p-tau217 was the most sensitive marker of cognitive decline, with hypertension contributing to longitudinal cognitive changes.</p>}},
  author       = {{Cottez, Rosalie J. and Peyrot, Clémence and Denis, Hélèna L. and Tremblay, Cyntia and Loiselle, Andréanne and Dallaire-Théroux, Caroline and Filali-Mouhim, Ali and Hébert, Sébastien S. and Leclerc, Nicole and Blennow, Kaj and Zetterberg, Henrik and Kergoat, Marie Jeanne and Calon, Frédéric and Pichet Binette, Alexa}},
  issn         = {{1552-5260}},
  keywords     = {{Alzheimer's disease; clinical progression; cognition; hypertension; longitudinal; mild cognitive impairment; p-tau217}},
  language     = {{eng}},
  number       = {{6}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort}},
  url          = {{http://dx.doi.org/10.1002/alz.71588}},
  doi          = {{10.1002/alz.71588}},
  volume       = {{22}},
  year         = {{2026}},
}